Advanced searches left 3/3

Carboplatin Paclitaxel - DOAJ

Summarized by Plex Scholar
Last Updated: 03 September 2022

* If you want to update the article please login/register

POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma

BackgroundSquamous carcinoma of the anal canal is a human papillomavirus-driven disease with poor prognosis in locally advanced or recurrent settings. Retinmilab's POD1UM-202 demonstrated robust clinical activity and an anticipated safety profile in patients with advanced SCAC who were undergoing platinum-based chemotherapy. The addition of retifranl to the existing care carboplatin-u2013paclitaxel in patients with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy will be included and stratified by PD-L1 expression, region, and severity of disease, according to POD13516. Patients will be given up to six induction cycles of carboplatin and paclitaxel every 28 days by SOC.

Source link: https://doi.org/10.3389/fonc.2022.935383

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions